A framework for decision making of migraine treatment with anti- CGRP monoclonal antibodies: a guide for real-world practice and public policies
Keywords:Migraine Disorders, Calcitonin Gene-Related Peptide, Algorithms, Antibodies, Monoclonal, Public Health
Anti-CGRP monoclonal antibodies have been developed for migraine preventive treatment. There is evidence of good efficacy and safety of these medications; however, cost is a factor that interferes with the choice of treatment. This paper proposes a framework in order to better assist the decision-making processes on the use of these drugs in developing countries without coverage of health care costs for migraine. The framework was built after reviewing phase II and III studies on episodic and chronic migraine treatment with erenumab, galcanezumab and fremanezumab.
How to Cite
Copyright (c) 2020 Headache Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.